RxDoctor Payments Data

Darpan Gandhi, MD

Nephrology · Charleston, SCNPI 1659635100

Payments from drug & device makers

$1,288in general payments, 2019–2025

Across 12 payments — averaging $107.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$310
  • Novartis$295
  • Novo Nordisk$126
  • Otsuka America Pharmaceutical, Inc.$117
  • Bayer$109
  • Ascendis Pharma Endocrinology Inc$92
  • plus $239 from 3 others

What the payments were for

  • Consulting fees$17514%
  • Food & beverage$1,11386%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,288 in reported general payments places this provider in the 40th percentile of 180 nephrology providers in South Carolina.

See all nephrology providers in South Carolina

Medicare billing

Part B allowed, 2024
$64,402
Medicare patients
192
Services billed
384

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin44$33,793
VeltassaPatiromer Calcium Sorbitex23$30,630
OzempicSemaglutide22$21,117
Potassium Citrate ErPotassium Citrate17$1,361
Losartan Potassium51$433
Carvedilol54$432
Torsemide35$338
Metoprolol Succinate21$215
Spironolactone22$127
Amlodipine Besylate41$126
Atorvastatin Calcium18$95
Tamsulosin Hcl15$91
Lisinopril27$70
Furosemide14$62
Omeprazole12$57

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$126$21,11722 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 180 nephrology providers in South Carolina.

Other nephrology in Charleston

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →